Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (September 2025)
29 slides from Maia Biotechnology's investor presentation, Sep 12, 2025
Slide 1: MAIA Biotechnology: Telomere Targeting Immunotherapies for Cancer
MAIA BIOTECHNOLOGY TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA September 2025
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are "forward-looking statements." These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; sta
Slide 3: Investment Profile
INVESTMENT PROFILE New science for cancer therapy with dual MoA: telomere targeting and immunogenicity. vy Lead molecule Ateganosine (THIO) in clinic y¥ Second generation compounds in R&D Phase 2 trial THIO-101 expansion in 2025: Ateganosine (THIO) + Libtayo® in NSCLC. vy Unprecedented disease contr
Slide 4: Ateganosine (THIO) Telomere Targeting Agent
Ateganosine (THIO) Telomere Targeting Agent ClinicalTrial Indication Treatment _Ateganosine > _Ateganosine > _Ateganosine > tislelizumab _Ateganosine > tislelizumab _Ateganosine > tislelizumab THIO-102-HCC Status Initiating Phase 3 Ongoing Phase 2 Planned Phase 2 Planned Phase 2 Planned Phase 2 Prec
Slide 5: Mission and Approach
MISSION AND APPROACH
Slide 6: Oncology Landscape
ONCOLOGY LANDSCAPE Cancer is the most dominant age-related disease Population aged >80 expected to triple by 2050 45 countries have life expectancy >80 years million Source: UN (World Social Report, 2023}; Worldometer (Life Expectancy of the World Population, 2024). a _ At age 90: 40% will be diagno
Slide 7: Novel Treatment
NOVEL TREATMENT Ateganosine (THIO) ; is the only direct telomere targeting anticancer agent in clinical development
Slide 8: Treatment with Ateganosine
REATMENT WITH ATEGANOSINE Ateganosine (THIO, 6-thio-2'-deoxyguanosine) Followed by has a novel dual mechanism of action Immune Checkpoint Inhibitor (CPI) @ Telomere targeting Examples of commercially available CPIs @ Immunogenic effect Wustavo | teVimera (cemiplimab) (tislelizumab) Shromaso REGENERO
Slide 9: Preclinical Studies in NSCLC
Preclinical Studies in NSCLC « Ateganosine (THIO) followed by CPI results in 60% complete response * Only 2 cycles of therapy were administered on weeks 1 and 2; no further therapy throughout the study * No recurrence after long-term follow-up * Anticancer immune memory has been induced: no cancer a
Slide 10: NSCLC Clinical Trials
NSCLC CLINICAL TRIALS
Slide 11: THIO-101 Phase 2 Trial with Libtayo in NSCLC
NYSE American: MAIA A Multicenter, Open-label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors Efficacy/Safety/Dose Selection Expansion / Registration
Slide 12: THIO-104 Phase 3 Pivotal Trial (Initiating)
THIO-104 PHASE 3 PIVOTAL TRIAL (INITIATING) A Multicenter, Open-label, Pivotal Phase 3 Trial Evaluating the Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors and Chemotherapy Pa NSCLO SL every 2 wees Mal Pa
Slide 13: Best Results in Third-Line NSCLC
BEST RESULTS IN THIRD-LINE NSCL THIO-104 (Pivotal Phase 2, ongoing): ¢ Median Overall Survival (OS) is at 17.8 months? 100 o 95% CI lower bound: 12.5 months o 99% CI lower bound: 10.8 months * The treatment has been generally well-tolerated to date in this heavily pre-treated population? Overall Sur
Slide 14: Expected Efficacy Results in NSCLC 3L
ECTED EFFI TALS IN NSCLC 3L THIO-101 Phase 2 Ateganosine + Libtayo° (n = 137-148) * CPI + Platinum Resistant Target Population * Prior treatment with docetaxel ORR >30%1 THIO-104 Pivotal Phase 3 Ateganosine + Libtayo® (n = 150) ¢ CPI + Platinum Resistant * Stratified: prior docetaxel vs. no prior do
Slide 15: Probability of Technical Success
PROBABILITY OF TECHNICAL SUCCESS THIO-104 Design Bayesian Assurance? Calculation * OSis the primary endpoint All 3L patients from THIO-101 * 90% power to detect HR=0.62, median 9.4 Control: months vs 5.8 months? (chemo) * Median OS assumption (literature): * Interim analysis boundary 1-sided p<0.007
Slide 16: Planned Trials in Other Tumor Types
PLANNED TRIALS IN OTHER TUMOR TYPES
Slide 17: Phase 2 Trials with Tislelizumab in CRC, SCLC and HCC
Multicenter, Open-label, Phase 2 Trials Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Tislelizumab in CRC, SCLC and HCC Part A/B: Part C: Pivotal Safety/Efficacy Signal (n Phase 2 (n THIO-102-CRC Immune as Colorectal Cancer Ateganosine > Activation -* Tisleli
Slide 18: Colorectal Rationale
COLORECTAL RATIONALE Preclinical Studies in Colorectal ~ Cancer (CRC) = ° Ateganosine (THIO) followed by CPI re results in 100% complete response 2 ° Only 2 cycles of therapy were : administered on weeks 1 and 2; no E further therapy throughout the study| 7 ¢ No recurrence after long-term follow-up
Slide 19: SCLC & HCC - Awarded Orphan Drug Designations
SCLC & HCC —- AWARDED ORPHAN Preclinical Studies in Small Cell Lung Cancer (SCLC) Ateganosine (THIO) is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung Carcinoma (H2081) in vivo in humanized murine cancer model Treatment with ateganosine (THIO) followed by Pembrolizumab results in
Slide 20: Excellent Efficacy in HCC Models
EXCELLENT EFFICACY IN HCC MODELS Ateganosine (THIO) achieved complete and durable responses in Hepatocellular Carcinoma (HCC), the dominant histology in primary liver cancer (90%), in in vivo models Tumor Volume (mm) 60074|-<- Control -&- Ateganosine 400- 2007 100% CR { 0 5 1015202530354045 Days Aft
Slide 21: HCC Combination with Libtayo and Immune Memory
* When combined with immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated ¢ Upon rechallenge with two times more cancer cells and no additional treatment, tumor growth was completely prevented ¢ Administration of ateganosine (THIO) alone and in combination with L
Slide 22: Investment Opportunity
INVESTMENT OPPORTUNITY
Slide 23: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Vlad Vitoc, MD, MBA Founder and CEO ul * 25+ years in Oncology Pharma/ Biotech: Commercial, Medical * 12 compounds launched across 20+ tumor types * Leadership roles at Bayer (Nexavar), Astellas (Tarceva, Xtandi), Cephalon (Treanda), Novartis (Zometa), Incyte (Jakafi) Ser
Slide 24: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY Goal: New Chemical Entity (NCE) Marketing Exclusivity + Ateganosine (THIO) has never been previously approved by the FDA for commercialization \ * Robust exclusivity o US: Upon FDA approval - 5 years NCE (with additional 2 years based on Hatch Waxman for potenti
Slide 25: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY (Rs) MALA ~.\ Developing agents for the top tumor types markets globally NSCLC (#1 WW) HCG Mortality: 1.7M / Sales: $34B | Mortality: 0.8M / Sales: $3B cRc (#2 WW) SCLC Mortality: 1.0M / Sales: $20B | Mortality: 0.3M / Sales: $2B S $50B CPIs Group (2024 Sales) ¢ 5CPIs
Slide 26: Comparable Companies
COMPARABLE COMPANIES ° August 2022 - Bristol Myers Squibb (BMS) completed $4.4B acquisition of Turning Point Therapeutics ¢ January 2024 - BMS completed $5.8B acquisition of Mirati Therapeutics 7 \ 1, Market cap and share price (close) as of September 10, 2025 (Source: Yahoo! Finance) 2. Last known
Slide 27: Thank You
THANK YOU Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 () MAIA Chicago, IL 60606 NYSE American: MAIA 27
Slide 28: Appendix
APPENDIX
Slide 29: Ateganosine (THIO) - U.S. FDA Designations
ATEGANOSINE (THIO) - U.S. FDA DESIGNATIONS 3 Orphan Drug Designations (ODD) @ Q Hepatocellular Carcinoma (HCC, 90% of primary liver cancers) Q Small Cell Lung Cancer (SCLC, deadliest lung cancer) QO Glioblastoma (brain cancer) * The FDA’s Orphan Drug Act of 1983 is designed to incentivize the develo
MAIA Biotechnology — Investor Presentation (September 2025) on 6ix